Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies

BACKGROUND: Adenosine inhibits the activation of most immune cells and platelets. Selective adenosine A2A receptor (A2AR) agonists such as regadenoson (RA) reduce inflammation in most tissues, including lungs injured by hypoxia, ischemia, transplantation, or sickle cell anemia, principally by suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabin, Joseph, Zhao, Yunge, Mostafa, Ezzat, Al-Suqi, Manal, Fleischmann, Emily, Conaway, Mark R., Mann, Barbara J., Chhabra, Preeti, Brayman, Kenneth L., Krupnick, Alexander, Linden, Joel, Lau, Christine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420352/
https://www.ncbi.nlm.nih.gov/pubmed/37566593
http://dx.doi.org/10.1371/journal.pone.0288920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420352/
https://www.ncbi.nlm.nih.gov/pubmed/37566593
http://dx.doi.org/10.1371/journal.pone.0288920

Ejemplares similares